IUGNF
Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a research collaboration with Celularity Inc. to develop the combination of Imugene's CD19 oncolytic virus technology and Celularity's CD19 targeting allogeneic chimeric antigen receptor T-cell therapy, CyCART-19 for the treatment of solid tumors; and has a strategic collaboration with Eureka Therapeutics, Inc. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2025 Q2 | -0.13 | $0 | -$26M |
| 2025 Q4 | -0.09 | $3M | -$34M |
| 2024 Q2 | -0.22 | $1M | -$49M |
| 2024 Q4 | -0.38 | -$3M | -$47M |
| 2023 Q2 | -0.34 | $8M | -$60M |
| 2023 Q4 | -0.11 | $7M | -$9M |
| 2022 Q2 | -0.10 | $5M | -$21M |
| 2022 Q4 | -0.14 | $8M | -$21M |